Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

MK-4074

Alternative Names: mk-4074, mk4074, mk 4074
Latest Update: 2024-01-09
Latest Update Note: PubMed Publication

Product Description

Merck was developing mk-4074, an oral ACC Inhibitor for Non-alcoholic Fatty Liver Disease

Mechanisms of Action: ACC Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Liver Diseases, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MK-4074-008

P1

Completed

Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Liver Diseases, Alcoholic

2012-09-18

Recent News Events

Date

Type

Title

01/09/2024

PubMed

 The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7.

07/07/2022

PubMed

 Mechanism and therapeutic strategy of hepatic TM6SF2-deficient non-alcoholic fatty liver diseases via in vivo and in vitro experiments.

07/21/2020

PubMed

 Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions